Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Vasogen and Grupo Ferrer Internacional have reported the receipt of initial orders for Vasogen's Celacade system, a first-in-class therapy for chronic heart failure, in Germany.
Subscribe to our email newsletter
In the international Acclaim trial, Celacade was shown to significantly reduce the risk of death or cardiovascular hospitalizations in large pre-specified subgroups of patients with chronic heart failure, including NYHA Class II patients, where risk was reduced by 39% and NYHA Class II to IV patients with no prior heart attack, where risk was reduced by 26%.
Vasogen said that the commercial introduction of Celacade in the EU will provide physicians and patients with a novel approach for the treatment of heart failure that is safe and well tolerated and can be used in combination with currently approved therapies for this condition.
Chris Waddick, president and CEO of Vasogen, said: “We look forward to continuing our close collaboration with Ferrer as we work to rapidly expand the use of Celacade within the EU.”